Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
1,582,162
-
Total 13F shares
-
59,161
-
Share change
-
-9,748
-
Total reported value
-
$97,407
-
Price per share
-
$1.65
-
Number of holders
-
8
-
Value change
-
-$18,661
-
Number of buys
-
2
-
Number of sells
-
3
Institutional Holders of Evoke Pharma, Inc. - Common Shares (EVOK) as of Q2 2023
As of 30 Jun 2023,
Evoke Pharma, Inc. - Common Shares (EVOK) was held by
8 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,161 shares.
The largest 9 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Tower Research Capital LLC (TRC), BlackRock Inc., UBS Group AG, NewEdge Advisors, LLC, Concord Wealth Partners, WELLS FARGO & COMPANY/MN, and Federation des caisses Desjardins du Quebec.
This page lists
9
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.